Coronary CT angiography-derived perivascular fat attenuation index as a potential marker for heart failure in hypertrophic cardiomyopathy.
Higher LAD perivascular fat attenuation independently linked to heart failure in hypertrophic cardiomyopathy
Coronary CT angiography-derived perivascular fat attenuation index as a potential marker for heart failure in hypertrophic cardiomyopathy.
This study aimed to evaluate coronary inflammation using the perivascular fat attenuation index (fat attenuation index) derived from coronary computed tomography angiography (coronary computed tomography angiography) in patients with hypertrophic cardiomyopathy (hypertrophic cardiomyopathy) and to investigate its association with heart failure (heart failure).
This retrospective study included 75 patients with hypertrophic cardiomyopathy and 75 age- and sex-matched controls without structural heart disease.
higher LAD fat inflammation independently raised heart failure odds in hypertrophic cardiomyopathy
Fat attenuation index values were significantly elevated in hypertrophic cardiomyopathy patients compared to controls across all three vessels: LAD-fat attenuation index (-75.49 ± 9.04 vs. -83.25 ± 8.97 HU), LCX-fat attenuation index (-71.96 ± 9.62 vs. -79.48 ± 8.51 HU), and RCA-fat attenuation index (-77.57 ± 10.25 vs. -83.20 ± 8.98 HU); all p < 0.001.
LAD-FAI demonstrated modest but significant correlations with markers of adverse left ventricular remodeling, including left ventricular mass index and global strain parameters.
Coronary inflammation, quantified by perivascular fat attenuation index on coronary computed tomography angiography, is significantly heightened in patients with hypertrophic cardiomyopathy and is correlated with left ventricular hypertrophy and dysfunction.
Notably, increased LAD-fat attenuation index is independently associated with heart failure after adjustment for the included CMR parameters, suggesting its potential utility as a non-invasive imaging biomarker for risk stratification in hypertrophic cardiomyopathy, pending external validation.